Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.34 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.34 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | APP | P05067 | 2/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14407267 | 0.90 | KDM4E (0.34) | KDM4EMAPTRAB9AGAAPIK3CD | |
| SCHEMBL286605 | 0.89 | MAPT (0.37) | KDM4EMAPTRAB9AGAAPIK3CD | |
| SCHEMBL286507 | 0.85 | KDM4E (0.39) | KDM4EMAPTRAB9AGAANPC1 | |
| SCHEMBL15000235 | 0.83 | RAB9A (0.41) | KDM4EMAPTRAB9AGAANPC1 | |
| SCHEMBL17239809 | 0.81 | PDE10A (0.37) | KDM4EMAPTRAB9AGAANPC1 | |
| SCHEMBL297504 | 0.81 | KDM4E (0.43) | KDM4EMAPTRAB9AGAANPC1 | |
| SCHEMBL298442 | 0.81 | MAPT (0.36) | KDM4EMAPTRAB9AGAAPDE10A | |
| SCHEMBL296229 | 0.80 | MAPT (0.59) | KDM4EMAPTRAB9AGAANPC1 | |
| SCHEMBL286674 | 0.80 | KDM4E (0.51) | KDM4EMAPTRAB9AGAANPC1 | |
| SCHEMBL15000232 | 0.79 | RAB9A (0.40) | KDM4EMAPTRAB9AGAANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100292238-A1 | Phenoxymethyl Heterocyclic Compounds | FMR LLC | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292238-A1 | Phenoxymethyl Heterocyclic Compounds | PDE3A, PDE2A, PDE5A | KDM4E 559/4885MAPT 1299/4885RAB9A 1008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.